Testing and Diagnostics Library
Every article, presentation, spotlight, and news item we've tagged to Testing and Diagnostics.
Showing 289–312 of 314
Home EEG tracking enables frequent Alzheimer's measurement
A year-long home-based study of 119 participants demonstrates that individuals with mild Alzheimer's disease can reliably self-administer frequent brain health assessments using a wireless EEG headset and cognitive task platform, achieving 99.7% completion rates and generating high-frequency data that may accelerate clinical trial design and reduce costs.
Virtual assistant enhances health outcomes in older adults with type 2 diabetes
A randomized controlled trial found that older adults with type 2 diabetes using a conversational AI virtual assistant achieved significantly better glycemic control and medication adherence compared to standard care. The intervention demonstrates that digital tools can reduce barriers to diabetes management in aging populations.
Correction to “The Activation of cGAS‐STING Pathway Causes Abnormal Uterine Receptivity in Aged Mice”
A published correction addresses methodological clarifications in research examining how the cGAS-STING innate immune pathway dysregulates uterine receptivity during aging. The work connects age-related immune activation to reproductive decline in mice, with implications for understanding fertility loss across aging.
Blood biomarkers bring Alzheimer's diagnosis to primary care
Imperial College London is integrating a blood-based biomarker test into primary care settings to enable earlier Alzheimer's detection before cognitive symptoms become severe. The study evaluates whether this approach can scale across healthcare systems to compress diagnostic timelines and support earlier clinical intervention.
There is no safe gamble with high LDL cholesterol
High LDL cholesterol carries cardiovascular risk regardless of body composition or metabolic phenotype. The concept of "lean mass hyper-responders"—individuals who gain muscle while maintaining low body fat despite elevated LDL—does not eliminate the atherogenic potential of circulating lipoproteins.
HPV Self-Testing Expands Cervical Cancer Prevention Access
Self-collected HPV testing at home offers a practical alternative to clinical Pap smears, potentially improving screening adherence by removing barriers to access and reducing friction in cervical cancer prevention. This shift from provider-administered to patient-directed screening represents a meaningful change in how early detection can reach broader populations.
Measuring intrinsic capacity at scale
Stanford-led THRIVE coalition secured $34.5 million to develop the first FDA-grade Intrinsic Capacity score, a composite measure integrating wearables, blood biomarkers, and functional assessments to predict 20-year health outcomes. This addresses the field's critical gap: the absence of regulatory-grade measurement infrastructure for aging itself, moving beyond disease-specific endpoints toward quantifiable functional decline.
Inflammation’s statin moment edges closer
BioAge's NLRP3 inhibitor BGE-102 produced marked reductions in inflammatory biomarkers (hsCRP, IL-6, fibrinogen) in Phase 1 testing, positioning upstream inflammasome inhibition as a potential scalable approach to chronic inflammation management. This advances a field that has lacked convenient, long-term preventive options despite growing evidence that inflammation drives cardiovascular and age-related disease.
APOE variants shape brain protein patterns before neurodegeneration
APOE ε2 and ε4 genetic variants produce distinct proteomic signatures that emerge before amyloid accumulation, mechanistically explaining their opposing effects on Alzheimer's disease risk. This proteomic mapping offers a foundation for identifying intervention points specific to genetic risk profiles rather than treating all cognitive decline uniformly.
Basecamp Research’s new gene atlas could speed longevity R&D
Basecamp Research's Trillion Gene Atlas expands genetic reference data 100-fold across 100 million species to improve AI drug discovery models for aging. The underlying premise is that current AI systems underperform not due to model limitations but because they train on narrow, repetitive biological data insufficient for solving complex, multisystem conditions like aging.
NeuroRPM to provide AI monitoring for Annovis Parkinson’s trial
NeuroRPM's FDA-cleared wearable platform will continuously monitor motor symptoms in a 500-participant Parkinson's disease trial, using Apple Watch data to measure bradykinesia, tremor, and dyskinesia with algorithmic precision. This represents the first FDA-cleared AI device for real-world Parkinson's symptom tracking, enabling detection of treatment response at granularity not achievable through standard clinical assessments alone.
Insilico, Tenacia expand AI-driven CNS collaboration
Insilico Medicine and Tenacia Biotechnology are expanding their AI-driven collaboration to design small-molecule therapies for central nervous system disorders, with a focus on blood-brain barrier penetration. This partnership demonstrates how generative AI can accelerate drug discovery for neurological conditions, including a candidate targeting NLRP3 inflammation that has cleared FDA review for Parkinson's disease trials.
Telomere Shortening Drives Atrial Fibrillation Through VCAM‐1 Mediated Atrial Electrical and Structural Remodeling
Telomere shortening drives atrial fibrillation through VCAM-1 upregulation, which promotes atrial fibrosis and electrical dysfunction. Blocking VCAM-1 reverses these changes and reduces AF susceptibility by 30%, identifying a mechanistic pathway linking cellular aging to arrhythmia risk.
Mild cognitive impairment cases affect the predictive power of Alzheimer’s disease diagnostic models using routine clinical variables
Mild cognitive impairment (MCI) cases substantially reduce the predictive accuracy of Alzheimer's disease diagnostic models built on routine clinical variables. This finding challenges the assumption that standard biomarkers and clinical assessments alone can reliably stratify progression risk in early cognitive decline.
Cognito Therapeutics presents Spectris data in Alzheimer’s disease
Cognito Therapeutics presented clinical and biomarker data supporting Spectris, a non-invasive neurostimulation therapy using synchronized light and sound to modulate gamma frequency brain waves in Alzheimer's disease. Prior studies showed preserved brain structure, slowed cognitive decline, and reduced atrophy compared with controls, with favorable safety profiles and no amyloid-related imaging abnormalities.
BioAge Reports Positive Phase 1 Data for BGE-102
BGE-102, a novel NLRP3 inhibitor, achieved profound and sustained reductions in high-sensitivity C-reactive protein (hsCRP) and multiple inflammatory biomarkers in Phase 1 trials, with 87% of obese participants with elevated inflammation reaching normalized hsCRP levels (<2 mg/L) at the lower 60 mg daily dose. This positions the compound as a potential best-in-class anti-inflammatory therapeutic for cardiovascular and metabolic disease prevention.
Early Memory Precision Detection Shifts Dementia Intervention Window
Prema Cognition has secured $730,000 in funding to expand PREMAZ, a digital cognitive assessment that detects memory decline years before conventional tests identify impairment. The tool addresses a critical gap in dementia detection: most therapeutic interventions work best in early disease stages, yet healthcare systems lack the sensitivity to identify patients at that window.
Multi‐Omics Analysis of Human Blood Cells Reveals Unique Features of Age‐Associated Type 2 CD8 Memory T Cells
Aging drives accumulation of a distinct CD8 T cell population lacking CXCR3 that exhibits Th2-skewed transcriptional and epigenetic programming. This shift correlates with increased risk for asthma, chronic liver disease, and type 2 diabetes, suggesting age-related immune dysregulation follows a predictable molecular trajectory.
Developing a Genetic Algorithm-Based Frailty Index for China Health and Retirement Longitudinal Study
Researchers developed a genetic algorithm-based frailty index using nine years of longitudinal data from the China Health and Retirement Longitudinal Study to predict mortality and falls risk in aging adults. This computational approach identifies which physiological and functional markers most reliably indicate vulnerability to adverse outcomes, providing a data-driven alternative to subjective clinical assessment.
Serum‐Derived Extracellular Vesicles as Biological Indicator of Mobility Resilience in Older Adults
Serum extracellular vesicles carry distinct molecular signatures—small noncoding RNAs and mitochondrial proteins—that differentiate older adults with preserved mobility from those with age-related gait decline. These circulating vesicles appear to mediate brain-muscle communication and may serve as noninvasive biomarkers for identifying individuals at risk of functional decline.
Intrinsic Capacity Decline Predicts Mortality 14 Years Early
Intrinsic capacity—the composite of physical, cognitive, and psychological abilities—shows measurable decline roughly 14 years before death, positioning it as a predictive marker for functional deterioration in aging populations. This finding supports the use of intrinsic capacity assessment as an early intervention point in clinical practice.
Proteomic markers detect liver disease 16 years early
Plasma proteomic signatures can identify individuals at risk for metabolic dysfunction-associated steatotic liver disease up to 16 years before clinical diagnosis. This early detection window creates an actionable interval for preventive intervention before hepatic pathology becomes established.
Risk-Stratified Breast Cancer Screening Reduces Harm
Breast cancer screening efficacy depends on individual risk stratification rather than one-size-fits-all mammography protocols. A risk-based framework allows clinicians to tailor screening modality, frequency, and timing to each person's specific risk profile, reducing unnecessary procedures while improving detection in high-risk populations.
Nautilus expands single-molecule proteomics into Parkinson’s
A $1.6 million collaboration between Nautilus Biotechnology, Weill Cornell Medicine–Qatar, and The Michael J Fox Foundation aims to detect alpha-synuclein proteoforms at single-molecule resolution to enable earlier Parkinson's disease diagnosis and subtype distinction. Current protein measurement tools average signals across millions of molecules, obscuring the structural variants that may drive disease progression and therapeutic response differently across individuals.